Clinical Trials Logo

Astrocytic Tumors clinical trials

View clinical trials related to Astrocytic Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT01967758 Completed - Clinical trials for Glioblastoma Multiforme

Phase I Study of Safety and Immunogenicity of ADU-623

Start date: January 8, 2014
Phase: Phase 1
Study type: Interventional

This is a study for patients with brain tumors called astrocytic tumors. The study will enroll patients who have received standard treatment. The study will test a vaccine called ADU-623. ADU-623 has not been tested in humans before, so the goal of this study is to see if ADU-623 can be given safely to brain cancer patients and what is the better dose to give patients among the three doses that planned to be tested. This study will also evaluate the length of time before patients' cancer worsens and if ADU-623 helps patients to live longer. The study will also measure the body's immune system response to ADU-623.

NCT ID: NCT01068782 Completed - Astrocytic Tumors Clinical Trials

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This is a study of multiple regimens of single-agent XL184 in subjects with grade IV astrocytic tumor in first or second relapse. The Randomized Phase of the study will evaluate the safety, tolerability, and preliminary efficacy of four XL184 dosing regimens in separate study arms. Subjects will be randomized to one of the study arms, which will not be blinded. After the Randomized Phase, additional subjects will be enrolled to further expand one study arm in the Expansion Phase.